
Commentary|Videos|September 4, 2025
The Future of GLP-1RAs in Obesity Treatment: Expert Perspective
Author(s)Sydney Jennings, Michael Crotty, MD
Fact checked by: Grace Halsey
With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.
Advertisement
The future of glucagon-like peptide-1 (GLP-1) receptor agonists in obesity treatment holds significant promise, though current challenges such as supply shortages, cost, and insurance coverage persist. The long-term success of GLP-1 receptor agonists hinges on a multifaceted approach that incudes lifestyle interventions, medication adherence, and addressing weight bias and stigma, according to Michael Crotty, MD, a general practitioner who specializes in obesity medicine and is co-founder of
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
4





























































































































































